May 20, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

Advances in Psoriasis and Inflammatory Skin Diseases

» Advanced search

Paper of the Month - September, 2010

Please login to access this article in full. Click here to register for free now!

Registered users login here:

Email Address:
Password:

If you have forgotten your password click here


0 rating

Effect of cyclosporine on blood pressure

Robert N, Wong GW, Wright JM.

Cochrane Database Syst Rev 2010;1:CD007893.

Cyclosporine is an immunosuppressant that is widely used in the treatment of autoimmune diseases such as psoriasis. However, one of the most common side-effects of this treatment is hypertension. It is therefore crucial that the range of increases in blood pressure that can occur following treatment with cyclosporine is known to enable adequate management of patients who are receiving the drug. Robert and co-authors carried out the current study to determine the effect of cyclosporine on blood pressure.

Please login or register to continue reading this article

View Archive »


Psoriasis and pregnancy outcomes: a nationwide population-based study - September, 2011
Isotretinoin influences pituitary hormone levels in acne patients - August, 2011
Eosinophil extracellular DNA traps in skin diseases - July, 2011
Recognizing psoriatic arthritis in the dermatology clinic - June, 2011
IL-1RL2 and its ligands contribute to the cytokine network in psoriasis - May, 2011
The role of T-cell reactivity towards the autoantigen α-NAC in atopic dermatitis - April, 2011
Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study - March, 2011
Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases - February, 2011
Pruritus is an important factor negatively influencing the wellbeing of psoriatic patients - January, 2011
International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis - June, 2010
Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system - July, 2010
Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema - September, 2010
Effect of cyclosporine on blood pressure - September, 2010
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis - October, 2010
The effect of adalimumab on reducing depression symptoms in patients with moderate-to-severe psoriasis: a randomized clinical trial - November, 2010
A comparison of three times vs. five times weekly narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis - December, 2010
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial - July, 2009
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways - June, 2009
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register - May, 2009
Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review - August, 2009
Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha blocker therapy - September, 2009
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) - October, 2009
Evaluation of the efficacy of acitretin therapy for nail psoriasis - November, 2009
Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crosssover study - December, 2009

READER POLL

Which therapy would you first use to treat a patient with newly diagnosed, severe plaque psoriasis?

Topical agents
Methotrexate
Anti-TNF agents
Cyclosporine
Phototherapy
Other

Find us on
Facebook

Post Page On

SUBMIT AN ARTICLE

» Click here

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

May 20, 2012 CLOSE To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader. Produced and published by Remedica Medical Education and Publishing Limited. » Contact us

Advances in Psoriasis and Inflammatory Skin Diseases » Advanced search